In a report issued on April 30, Umer Raffat from Evercore ISI maintained a Buy rating on Phathom Pharmaceuticals (PHAT). The company’s shares closed last Friday at $38.52.
According to TipRanks.com, Raffat is a 2-star analyst with an average return of 2.6% and a 52.1% success rate. Raffat covers the Healthcare sector, focusing on stocks such as Kodiak Sciences, Vor Biopharma, and Athenex.
Currently, the analyst consensus on Phathom Pharmaceuticals is a Strong Buy with an average price target of $61.00, representing a 66.0% upside. In a report issued on April 29, JonesTrading also reiterated a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Phathom Pharmaceuticals’ market cap is currently $1.1B and has a P/E ratio of -10.30. The company has a Price to Book ratio of 5.85.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PHAT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.